MiNK Therapeutics(US:INKT)2025-12-08 21:10Clinical Trials and Research - MiNK Therapeutics reported a median overall survival of approximately 23 months for patients receiving agenT-797 in combination with PD-1 therapies, significantly exceeding the expected survival of under six months in a refractory setting [7]. - The company observed a complete remission in a patient with metastatic testicular cancer lasting over two years following a single infusion of agenT-797 combined with PD-1 blockade [26]. - The company is preparing for a global Phase II trial in acute pulmonary dysfunction, with the study expected to launch within weeks [19]. - The Phase I study of agenT-797 demonstrated durable activity across various tumor types, with nearly half of patients having failed PD-1 ligand inhibitors [25]. - The primary endpoint for the pulmonary disease trial will be 28-day mortality, with additional secondary and exploratory endpoints being established [71]. - The company anticipates launching the severe pulmonary disease trial with the first patient targeted for enrollment by early Q1 of next year [54]. - The GvHD trial is funded through a partnership with government collaborators and aims to improve engraftment success without the need for cytotoxic lymphodepletion [60]. - The GvHD program aims for a significant reduction in GvHD incidence, targeting a 50% improvement or more, which would be substantially beneficial [63]. - MiNK Therapeutics aims to redefine immune recovery in cancer and critical illness, focusing on reeducating the immune system rather than suppressing it [35]. - The company is actively engaging with the FDA to ensure rapid development pathways for its clinical programs [64]. Financial Performance - The cash balance at the end of Q3 2025 was $14.3 million, with an additional $1.2 million raised since the quarter end, providing a runway through 2026 [36]. - The net loss for Q3 2025 was $2.9 million, or $0.65 per share, compared to a net loss of $1.8 million, or $0.46 per share, for Q3 2024 [36]. - For the nine months ended September 30, 2025, the net loss was $9.9 million or $2.39 per share, compared to a net loss of $8.3 million or $2.24 per share for the same period in 2024 [38]. - The company executed an at-the-market sales agreement, leveraging a more than 700% increase in equity price, which extended the cash runway through 2026 [42]. - The company is exploring nondilutive financing options to expand its manufacturing infrastructure beyond current capabilities [76]. Partnerships and Collaborations - The company has established a strategic partnership with the University of Wisconsin to advance its iNKT program in immune reconstitution following stem cell transplantation [15]. - The company is leveraging public-private partnerships, including support from the Department of Defense and NIH, to advance its clinical programs with minimal capital impact [17]. - Discussions are ongoing with collaborators in both the private and public sectors to leverage substantial scale and interest [79]. Manufacturing and Production - The company is currently able to produce 1 billion cells per donor, which provides substantial cost advantages and the ability to stockpile materials for trials [76]. - The cells have demonstrated stability for almost 3 years, indicating potential for continued production at scale [77]. - The company is preparing for future opportunities based on the current stability of their products [77].